| Dr Matthew Gordon Salter, DO | |
|
593 Eddy Street, Davol 129, Providence, RI 02903-4923 | |
| (401) 444-4933 | |
| (401) 444-5090 |
| Full Name | Dr Matthew Gordon Salter |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 18 Years |
| Location | 593 Eddy Street, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093955171 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 5101017739 (Michigan) | Secondary |
| 207L00000X | Anesthesiology | 00695 (Rhode Island) | Secondary |
| 207L00000X | Anesthesiology | DO00695 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital - Farmington Hills | Farmington hills, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Botsford Anesthesiologists, Pc | 5890682181 | 7 |
News Archive
Researchers at University College London say they have gleaned a key insight into the molecular beginnings of age-related macular degeneration, the No. 1 cause of vision loss in the elderly, by determining how two key proteins interact to naturally prevent the onset of the condition.
The National Institutes of Health (NIH) and its partners will host a meeting of researchers, clinicians, patients and patient advocates to discuss spinal cord injury (SCI) research and to chart a course of future studies.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the intended treatment of acute pain, reported that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has confirmed that a Marketing Authorization Application (MAA) for ARX-04 may be submitted in the European Union (EU) under the Agency's centralized procedure.
A brain-training task that increases the number of items an individual can remember over a short period of time may boost performance in other problem-solving tasks by enhancing communication between different brain areas.
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has announced a positive opinion of ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells for designation as an orphan medicinal product for the treatment of Stargardt's disease.
› Verified 8 days ago
| Entity Name | Botsford Anesthesiologists, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285676460 PECOS PAC ID: 5890682181 Enrollment ID: O20040302000377 |
News Archive
Researchers at University College London say they have gleaned a key insight into the molecular beginnings of age-related macular degeneration, the No. 1 cause of vision loss in the elderly, by determining how two key proteins interact to naturally prevent the onset of the condition.
The National Institutes of Health (NIH) and its partners will host a meeting of researchers, clinicians, patients and patient advocates to discuss spinal cord injury (SCI) research and to chart a course of future studies.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the intended treatment of acute pain, reported that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has confirmed that a Marketing Authorization Application (MAA) for ARX-04 may be submitted in the European Union (EU) under the Agency's centralized procedure.
A brain-training task that increases the number of items an individual can remember over a short period of time may boost performance in other problem-solving tasks by enhancing communication between different brain areas.
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has announced a positive opinion of ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells for designation as an orphan medicinal product for the treatment of Stargardt's disease.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Matthew Gordon Salter, DO One Virginia Avenue, Suite 201, Providence, RI 02905 Ph: (401) 490-0916 | Dr Matthew Gordon Salter, DO 593 Eddy Street, Davol 129, Providence, RI 02903-4923 Ph: (401) 444-4933 |
News Archive
Researchers at University College London say they have gleaned a key insight into the molecular beginnings of age-related macular degeneration, the No. 1 cause of vision loss in the elderly, by determining how two key proteins interact to naturally prevent the onset of the condition.
The National Institutes of Health (NIH) and its partners will host a meeting of researchers, clinicians, patients and patient advocates to discuss spinal cord injury (SCI) research and to chart a course of future studies.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the intended treatment of acute pain, reported that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has confirmed that a Marketing Authorization Application (MAA) for ARX-04 may be submitted in the European Union (EU) under the Agency's centralized procedure.
A brain-training task that increases the number of items an individual can remember over a short period of time may boost performance in other problem-solving tasks by enhancing communication between different brain areas.
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has announced a positive opinion of ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells for designation as an orphan medicinal product for the treatment of Stargardt's disease.
› Verified 8 days ago
Dr. Keith-austin Scarfo, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Apc 6, Providence, RI 02903 Phone: 401-444-3777 Fax: 401-444-7249 | |
Dr. William Arthur Yelle, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 825 Chalkstone Ave, Providence, RI 02908 Phone: 401-456-2000 | |
Dr. Joshua Kenneth Potvin, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-606-4286 Fax: 401-444-5090 | |
Dr. Henry Huang, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5172 Fax: 401-444-5090 | |
Jonathan D Uri, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy Street, Davol 129, Providence, RI 02903 Phone: 401-444-4933 Fax: 401-444-5090 | |
Joseph Caiati, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 593 Eddy Street, Davol 129, Providence, RI 02903 Phone: 401-444-4933 Fax: 401-444-5090 | |
Bruce Winter, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 101 Dudley St, Women & Infants Hospital, Providence, RI 02905 Phone: 401-274-1122 Fax: 401-453-7533 |